Claudia Hopenhayn1, Amy Christian, Warren Jay Christian, Meg Watson, Elizabeth R Unger, Charles F Lynch, Edward S Peters, Edward J Wilkinson, Youjie Huang, Glenn Copeland, Wendy Cozen, Maria Sibug Saber, Marc T Goodman, Brenda Y Hernandez, Martin Steinau, Christopher Lyu, Thomas T Tucker, Mona Saraiya. 1. 1Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY; 2Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, and 3Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA; 4Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA; 5Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA; 6Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL; 7Florida Department of Health, Tallahassee, FL; 8Michigan Department of Community Health, Lansing, MI; 9Norris Comprehensive Cancer Center and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA; 10University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI; 11Battelle Memorial Institute, Durham, NC; and 12Markey Cancer Control Program, University of Kentucky, Lexington, KY.
Abstract
OBJECTIVE: We conducted a baseline study of human papillomavirus (HPV) type prevalence in invasive cervical cancers (ICCs) using data from 7 cancer registries (CRs) in the United States. Cases were diagnosed between 1994 and 2005 before the implementation of the HPV vaccines. MATERIALS AND METHODS: Cancer registries from Florida, Kentucky, Louisiana, Michigan, Hawaii, Iowa, and Los Angeles, California identified eligible ICC cases and obtained sections from representative blocks of archived tumor specimens for DNA extraction. All extracts were assayed by linear array and, if inadequate or HPV negative, retested with INNO-LiPA Genotype test. Clinical and demographic factors were obtained from the CRs and merged with the HPV typing data to analyze factors associated with different types and with HPV negativity. RESULTS: A total of 777 ICCs were included in this analysis, with broad geographic, age, and race distribution. Overall, HPV was detected in 91% of cases, including 51% HPV-16, 16% HPV-18 (HPV-16-negative), and 24% other oncogenic and rare types. After HPV-16 and -18, the most common types were 45, 33, 31, 35, and 52. Older age and nonsquamous histology were associated with HPV-negative typing. CONCLUSIONS: This study provides baseline prevaccine HPV types for postvaccine ICC surveillance in the future. HPV-16 and/or -18 were found in 67% of ICCs, indicating the potential for vaccines to prevent a significant number of cervical cancers.
OBJECTIVE: We conducted a baseline study of human papillomavirus (HPV) type prevalence in invasive cervical cancers (ICCs) using data from 7 cancer registries (CRs) in the United States. Cases were diagnosed between 1994 and 2005 before the implementation of the HPV vaccines. MATERIALS AND METHODS: Cancer registries from Florida, Kentucky, Louisiana, Michigan, Hawaii, Iowa, and Los Angeles, California identified eligible ICC cases and obtained sections from representative blocks of archived tumor specimens for DNA extraction. All extracts were assayed by linear array and, if inadequate or HPV negative, retested with INNO-LiPA Genotype test. Clinical and demographic factors were obtained from the CRs and merged with the HPV typing data to analyze factors associated with different types and with HPV negativity. RESULTS: A total of 777 ICCs were included in this analysis, with broad geographic, age, and race distribution. Overall, HPV was detected in 91% of cases, including 51% HPV-16, 16% HPV-18 (HPV-16-negative), and 24% other oncogenic and rare types. After HPV-16 and -18, the most common types were 45, 33, 31, 35, and 52. Older age and nonsquamous histology were associated with HPV-negative typing. CONCLUSIONS: This study provides baseline prevaccine HPV types for postvaccine ICC surveillance in the future. HPV-16 and/or -18 were found in 67% of ICCs, indicating the potential for vaccines to prevent a significant number of cervical cancers.
Authors: Charlene A Wong; Mona Saraiya; Susan Hariri; Linda Eckert; Roberta I Howlett; Lauri E Markowitz; Julia M L Brotherton; Katy Sinka; Olga G Martinez-Montañez; Susanne K Kjaer; Eileen F Dunne Journal: Vaccine Date: 2010-11-05 Impact factor: 3.641
Authors: Mona Saraiya; Faruque Ahmed; Sheila Krishnan; Thomas B Richards; Elizabeth R Unger; Herschel W Lawson Journal: Obstet Gynecol Date: 2007-02 Impact factor: 7.661
Authors: Wiebren A Tjalma; Alison Fiander; Olaf Reich; Ned Powell; Andrzej M Nowakowski; Benny Kirschner; Robert Koiss; John O'Leary; Elmar A Joura; Mats Rosenlund; Brigitte Colau; Doris Schledermann; Kersti Kukk; Vasileia Damaskou; Maria Repanti; Radu Vladareanu; Larisa Kolomiets; Alevtina Savicheva; Elena Shipitsyna; Jaume Ordi; Anco Molijn; Wim Quint; Alice Raillard; Dominique Rosillon; Sabrina Collas De Souza; David Jenkins; Katsiaryna Holl Journal: Int J Cancer Date: 2012-07-24 Impact factor: 7.396
Authors: Meg Watson; Mona Saraiya; Faruque Ahmed; Cheryll J Cardinez; Marsha E Reichman; Hannah K Weir; Thomas B Richards Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Sean F Altekruse; Gabriel E Rosenfeld; Danielle M Carrick; Emilee J Pressman; Sheri D Schully; Leah E Mechanic; Kathleen A Cronin; Brenda Y Hernandez; Charles F Lynch; Wendy Cozen; Muin J Khoury; Lynne T Penberthy Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-12 Impact factor: 4.254
Authors: Jacqueline Mix; Mona Saraiya; Benjamin D Hallowell; Brian Befano; Li C Cheung; Elizabeth R Unger; Julia W Gargano; Lauri E Markowitz; Philip E Castle; Tina Raine-Bennett; Joan Walker; Rosemary Zuna; Mark Schiffman; Nicolas Wentzensen; Julia C Gage Journal: J Natl Cancer Inst Date: 2022-06-13 Impact factor: 11.816
Authors: Jennifer C Spencer; Noel T Brewer; Tamera Coyne-Beasley; Justin G Trogdon; Morris Weinberger; Stephanie B Wheeler Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-09 Impact factor: 4.254
Authors: Amy J Blatt; Ronald Kennedy; Ronald D Luff; R Marshall Austin; Douglas S Rabin Journal: Cancer Cytopathol Date: 2015-04-10 Impact factor: 5.284
Authors: Cecilie Dovey de la Cour; Sonia Guleria; Mari Nygård; Laufey Trygvadóttir; Kristjan Sigurdsson; Kai-Li Liaw; Maria Hortlund; Camilla Lagheden; Bo T Hansen; Christian Munk; Joakim Dillner; Susanne K Kjaer Journal: Cancer Med Date: 2019-01-11 Impact factor: 4.452
Authors: Rachel F Shenker; Nelson H May; Joshua D Waltonen; Jae Paul Yang; Stacey S O'Neill; Bart A Frizzell; Kathryn M Greven; Ryan T Hughes Journal: Head Neck Pathol Date: 2021-02-22